加载中…
Place · Level 3
心脏泵、血管内皮、脂蛋白交通、斑块演化和血压调控共同决定循环质量
synergy · 5
Cardiac output + O₂ transport + muscle extraction determine VO2max. Mandsager 2018 JAMA Open: high VO2max → all-cause mortality ↓5×, larger than any single CV intervention's effect.
Long-term Zone 2 → mitochondrial biogenesis + capillary density + endothelial NO. The deepest cardiovascular adaptations come from low-intensity volume, not short high-intensity bursts.
High-dose EPA (4g/d icosapent ethyl) in REDUCE-IT (N=8,179) cut major CV events 25%; standard fish-oil dose (1g/d EPA+DHA) showed modest/null effects in VITAL / ASCEND. Dose, form, and patient stratification matter.
Fish-oil clinical benefit depends entirely on actual EPA+DHA dose and baseline TG. The 'fish oil protects the heart' claim is marketing oversimplification; the strongest evidence is for icosapent ethyl in high-TG + high-CV-risk patients.
Q-SYMBIO (Mortensen 2014, N=420, chronic HF) CoQ10 100 mg × 3/d × 2 yr halved all-cause and CV mortality. Statin therapy depletes endogenous CoQ10, plausibly contributing to myalgia (Banach 2015 meta: 100-200 mg/d reduces statin-associated myalgia).
regulates · 14
Fat type affects LDL-C and cardiovascular risk factors; replacement matters more than total fat alone.
Shift work is IARC 2A and long-term CHD ↑19% (Vetter 2016 JAMA) — circadian misalignment stacks sympathetic surge + inflammation + MetSyn.
OSA → intermittent hypoxia + sympathetic surge + dawn BP spikes → HTN/AF/CHF. SURMOUNT-OSA 2024 cut AHI −25 to −29.
Chronic hypoxia (COPD/OSA) → HIF-1α → pulmonary vasoconstriction → pulmonary hypertension → cor pulmonale. Cardiovascular events are the leading cause of death in respiratory patients.
Libby 2011 NEJM: atherosclerosis is chronic inflammation, not plumbing. Macrophage foam cells + adaptive immunity drive plaque progression — hs-CRP is the clinical inflammation marker.
Liver is the lipid hub: VLDL export → peripheral fat deposition; NASH patients carry 2-3× CVD risk. 'Fatty liver is not just a liver problem' has a molecular basis.
Autonomic nervous system (vagal/sympathetic) directly controls HR and vascular tone — HRV is the simplest non-invasive index of neural-cardiac integration; chronic stress keeps sympathetic locked on, elevating CVD risk.
Estrogen vasoprotection (↑NO, ↓LDL, endothelial stability) → perimenopausal estrogen drop is the female CVD inflection point. Early menopause / oophorectomy → CVD 5-10 yr earlier. In men, low T + high E2 (fat aromatase) is similarly CV-adverse.
Cardiorenal syndrome: CKD is the #1 cardiovascular mortality risk factor; reverse — heart failure is the #1 in-hospital cause of AKI. Bidirectional mechanisms (RAAS + volume + chronic inflammation + uremic toxins). Treating one often misses the other.
With oestrogen gone the lipid profile drifts the wrong way (LDL up, HDL function down), lifting cardiovascular risk on top of existing factors. Monitoring LDL through this period, and discussing a statin where indicated, is baseline care.
Blood volume, sodium-water handling, and potassium intake shape circulatory load and blood pressure.
Marfella 2024 NEJM (N=257 CEA): patients with MNP in carotid plaque had 3-yr MACE HR 4.53. Observational, awaits replication, plausible mechanism.
Vitamin E stops a radical in the lipid phase and becomes a tocopheroxyl radical (TO•) itself, which vitamin C has to reduce back. High-dose E alone lets TO• accumulate — part of the chemistry behind large trials finding no cardiovascular benefit from E.
Curcumin does carry an anti-inflammatory signal, but much of its in-vitro 'treats everything' performance comes from it being an assay-interfering compound, on top of very poor oral absorption. As the mainstay of an anti-inflammatory cardiovascular plan, the magnitude is wrong.